Transient heart rate reduction improves acute decompensated heart failure-induced left ventricular and coronary
Nicolas Peschanski1, Najah Harouki1,2, Matthieu Soulie1
1Normandie Université, UNIROUEN, Inserm U1096 Endothelium, Valvulopathy and Heart Failure, Rouen, 76183, France.
ESC Heart Failure
|January 20, 2021
Summary
Early heart rate reduction (HRR) in acute decompensated heart failure (ADHF) improved cardiovascular function and prevented pulmonary congestion. These benefits persisted even after treatment cessation, suggesting a potential therapeutic strategy for ADHF.
Area of Science:
- Cardiovascular Physiology
- Heart Failure Research
- Pharmacological Interventions
Background:
- Acute decompensated heart failure (ADHF) involves worsening cardiac function and increased heart rate.
- Existing heart failure (HF) treatments do not always address the acute decompensation phase effectively.
Purpose of the Study:
- To investigate if heart rate reduction (HRR) can counteract the cardiovascular dysfunction associated with ADHF.
- To evaluate the efficacy of early versus delayed HRR in a novel rat model of ADHF.
Main Methods:
- A rat model of ADHF was established using salt-loading post-coronary ligation.
- Heart rate reduction was induced using the If current inhibitor S38844.
- Cardiac output, myocardial perfusion, pulmonary weight, and coronary artery relaxation were assessed.
Main Results:
- Early HRR with S38844 rapidly improved cardiac output, myocardial perfusion, and coronary relaxation.
- These improvements persisted for 14 days post-treatment, and pulmonary congestion was reduced.
- Delayed HRR did not show significant improvements in cardiac function.
Conclusions:
- Early, transient HRR in ADHF opposes cardiovascular deterioration and pulmonary congestion.
- The beneficial effects of early HRR extend beyond the treatment period.
- Further research is warranted to explore HRR agents in human ADHF.
More Related Videos
08:19Transthoracic Echocardiography to Assess Post-Resuscitation Left Ventricular Dysfunction After Acute Myocardial Infarction and Cardiac Arrest in Pigs
Published on: July 12, 2022
3.1K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.8K
Related Concept Videos
01:30Heart Failure V: Medical Management
92
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
92
01:29Heart Failure II: Pathophysiology
230
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
230
01:30Cardiomyopathy II: Dilated Cardiomyopathy
152
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
152
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
671
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
671
01:22Heart Failure Drugs: β-Blockers
562
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
562
01:17Pathophysiology of Heart Failure
2.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K